Select Page

South Delhi Pharma, New Delhi, India

Jakafi (Ruxolitinib) tablets, for oral use

(8 customer reviews)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email to discuss.

Facts of Jakafi (Ruxolitinib)

Product: JAKAFI® (ruxolitinib) tablets, for oral use
Indication: bone marrow disorders (myelofibrosis, polycythemia vera).
Strength: Tablets: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.
Company: Incyte Corporation

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Jakafi (Ruxolitinib) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Jakafi (Ruxolitinib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.


Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

What Jakafi is?

Jakafi is a kinase inhibitor indicated for treatment of:

  • intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.
  • polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.
  • steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.

What Ruxolitinib is?

Ruxolitinib (trade names Jakafi and Jakavi) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea. Ruxolitinib has also been shown to improve cases of chronic graft versus host disease in patients following a bone marrow transplant.

Ruxolitinib is a janus kinase inhibitor (JAK inhibitor) with selectivity for subtypes JAK1 and JAK2. Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.

8 reviews for Jakafi (Ruxolitinib) tablets, for oral use

  1. Elvin Zirk

    Can I just say what a relief to find someone who actually knows what theyre talking about on the internet. You definitely know how to bring an issue to light and make it important. More people need to read this and understand this side of the story. I cant believe youre not more popular because you definitely have the gift.

  2. skyhub canada

    Este site é realmente incrível. Sempre que acesso eu encontro coisas incríveis Você também vai querer acessar o nosso site e saber mais detalhes! conteúdo único. Venha descobrir mais agora! 🙂

  3. InessaOlmr

    coursework help
    [url=””]cpa coursework[/url]
    buy coursework online

  4. raixete

    1990 identified a 188C T transition in exon 1 of more best site to buy cialis online

  5. emultetly

    Farooki ZQ, Ross RD, Paridon SM, et al online generic cialis

  6. Priopay

    Even when fighting, many diabetes medication trigenta of him could not let go of his hands and feet non prescription cialis online pharmacy

  7. thyloalty

  8. Gawaddelm

    AIs are also important for PCT when you re including Human Chorionic Gonadotropin HCG in your PCT protocol, since aromatase inhibitors are needed to moderate the estrogenic effects in HCGs femara vs clomid 6 Foods That May Affect Breast Cancer Risk

Add a review

Your email address will not be published. Required fields are marked *